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We investigated the antioxidant potential, cytotoxic eﬀect, and TNF-α inhibition activity with NF-κB activation response in a
chloroformfractionofCentratherumanthelminticumseeds(CACF).TheantioxidantpropertyofCACFwasevaluatedwithDPPH,
ORAC, and FRAP assays, which demonstrated signiﬁcant antioxidant activity. The cytotoxicity of CACF was tested using the MTT
assay; CACF eﬀective inhibitory concentrations (IC50) for A549, PC-3, MCF-7, and WRL-68 cells were 31.42 ± 5.4, 22.61 ± 1.7,
8.1±0.9, and 54.93±8.3μg/mL, respectively. CACF eﬀectively and dose-dependently inhibited TNF-α release, in vitro and in vivo.
CACFinhibitedTNF-αsecretioninstimulatedRAW264.7macrophagesupernatantswithanIC50 of0.012μg/mL,withoutaﬀecting
their viability; the highest dose tested reduced serum TNF-α by 61%. Acute toxicity testing in rats revealed that CACF was non-
toxicatalldosestested.Matchingthecytotoxicactivitytowardsamechanisticapproach,CACFdose-dependentlyexhibitedinvitro
inhibitory eﬀects against the activation of NF-κB translocation in MCF-7 cells. Preliminary phytochemical screening with GC/MS
analysis detected 22 compounds in CACF, of which morpholinoethyl isothiocyanate was the most abundant (29.04%). The study
reveals the potential of CACF in the treatment of breast cancer and in oxidative stress conditions with associated inﬂammatory
responses.
1.Introduction
Since time immemorial, traditional herbs have been used as
remedies for several diseases [1]. Even though new synthetic
drugs are available, traditional medicine is still being utilized
today as part of primary healthcare in several parts of the
world. Traditional medicine is often sought because it is
economical, readily available, and trusted by its advocate
[2]. Studies on herbal medicines have shown the positive
correlation of traditional claims and scientiﬁc data [3]. Some
of these traditional treatments are part of clinical practice,
and few are found to be not beneﬁcial [4]. Support for
traditional medicine and the numerous natural products
with biological activity have led to multidisciplinary inves-
tigations utilizing preliminary screening procedures as well
as advanced mechanistic studies to develop drugs which may
be used clinically.
Centratherum anthelminticum (L.) KUNTZE (family:
Asteraceae) is an erect, pubescent annual herb found widely
in the Indian subcontinent which is locally known as
“Somraj,” and its seeds are known as “Kalijiri” in Hindi
[5, 6]; scientiﬁc synonyms for this plant include Vernonia
anthelmintica and Conyza anthelmintica, among others. This
plant is used extensively in Ayurveda for the treatment of
cough and diarrhoea, as well as an anthelmintic, stomachic,
diuretic, and antiphlegmatic agent [5, 7]. Experimental
studies proved the pharmacological eﬀects of this plant’s
seeds extract, including antihelminthic [8], larvicidal [9],
antipyretic [10], antiﬁlarial [11], antihyperglycemic [12],
antimicrobial [13], and diuretic [14] activities. In addition2 Evidence-Based Complementary and Alternative Medicine
to primary metabolites, the seeds of this plant contain gly-
cosides, phenolic compounds, tannins, ﬂavonoids, saponins,
and sterols [15]. Examples of secondary metabolites found
in C. anthelminticum include the following: ﬂavonoids such
as 2 ,3,4,4-tetrahydroxychalcone (Butein); 5,6,7,4 -tetra-
hydroxy ﬂavone and 7,3 ,4 -trihydroxydihydroﬂavone [16];
sterolssuchassterol-4-alpha-methylvernosterol,vernosterol,
and avernosterol [17]; steroids such as (24a/R)-stigmasta-
7-en-3-one,24(a/R)-stigmasta-7,9(11)-dien-3-one,24(a/S)-
stigmasta-5and22-dien-3β-ol, stigmasta-7,and22-dien-3β-
ol [18].
While several studies investigated the pharmacological
eﬀects of this plant, the antiinﬂammatory and anti-cancer
activities are yet to be investigated. Inﬂammation is a natural
defense mechanism by the host which plays a role in
various diseases. Immune cells are particularly important in
inﬂammation because they orchestrate the release of several
mediators such as cytokines, prostaglandins, and nitric
oxide, which play a part in the defense process. However,
uncontrolled production of these mediators is associated
with tissue damage due to oxidative stress [19]. Oxidative
stress resulting from reactive oxygen and nitrogen species
(ROS and RNS) was shown to cause DNA mutations and
cell death and aﬀect cell proliferation. Cells which survive
the DNA damage caused by oxidative stress are likely to
have aberrant repair mechanisms, the proliferation of these
genetically instable cells might eventually progress toward
carcinogenesis. Therefore, this study looked into the antiox-
idant approaches, the in vitro and in vivo TNF inhibition
activity counting cytotoxic eﬀect in the chloroform fraction
with further evaluation of linkage between NF-κBa c t i v a t i o n
on breast cancer (MCF-7) cell lines.
2.MaterialsandMethods
2.1. Cell Lines and Reagents. A l lc e l ll i n e sw e r ep u r c h a s e d
fromATCC(Rockville,MD,USA).RPMImedium,penicillin
and streptomycin solution, and phosphate buﬀer Saline
(PBS) were purchased from Invitrogen (Rockville, MD,
USA). MTT, DMSO, and heat-inactivated fetal bovine
serum and 0.25% trypsin solution were purchased from
Sigma-Aldrich Chemicals (Saint Louis, MO, USA). Cell
culture treated 96-well plates, and cell culture ﬂasks were
purchased from Orange Scientiﬁc (Braine-l’Alleud, Bel-
gium). PBS 75nM, pH Dulbecco’s Modiﬁed Eagle Medium
(DMEM), phosphate buﬀered saline, Hanks’ balanced
salt solution (HBSS), and 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were from Invitrogen
(Carlsbad, USA). Fetal bovine serum (FBS), LPS from E.
coli serotype 0111:B4, and dimethylsulfoxide (DMSO) were
obtainedfromSigma(St.Louis,USA).MurineTNF-αELISA
kitwasfromeBioscience(SanDiego,USA).NF-κBactivation
kit from Thermo Scientiﬁc Cellomics, ﬂuorescence sodium
salt, DPPH and FRAP reagents, Pentoxifylline and Pacli-
taxel (Sigma-Aldrich), AAPH, Quercetin, and Trolox were
from Sigma-Aldrich Chemicals (S. Louis, MO, USA). Plates
were read using Chameleon V Multilabel microplate reader
(Hidex, Turku; Finland) in 96-well format black plate.
2.2. Plant Materials. The seeds of the plant Centratherum
anthelminticum were procured from the medicinal plant
cultivation zone of Amritum Bio-Botanica Herbs Research
Laboratory Pvt. Ltd, Betul, Madhya Pradesh, India. The
seeds of the plant were authenticated by the Quality Control
department of the company itself. Voucher specimen (CA-
9) is deposited in the Pharmacology Department of the
University of Malaya, Malaysia.
2.3. Extraction Procedure. The coarsely powdered seeds
(100g) were extracted with water:ethanol (80:20) using
a Soxhlet extractor for 24h (Figure 1). The solvent was
completely evaporated using rotary evaporator. The brown
viscous crude extract weighing (49% w/w) obtained was
further fractionated successively with hexane, chloroform
and methanol, then the solvent from each fraction was
completely recovered with the help of rotary evaporator
under reduced pressure. After drying, the ﬁnal yields with
hexane (CAHF), chloroform(CACF), and methanol fraction
(CAMF) were (19.41% w/w), (4.11 w/w), and (11.3% w/w),
respectively. Then the dried fractions were kept below
−20◦C before being used. The in pilot bioactivity testing,
chloroform fraction (CACF) had shown the positive eﬀect
and hence was chosen for further analysis.
2.4. Animals. Altogether 72 Sprague Dawley rats of 150–
200g were obtained from the University of Malaya Medical
Centre Animal House and maintained under standard
conditions of lighting (12h of light and darkness) and
nutrition (food and water ad libitum) throughout the
experimental period. Studies were performed in accordance
with the Medical Research Council Guidelines on Ethics in
Animal Experimentation. This study was approved by the
Animal Experimentation ethics committee at the University
of Malaya Medical Center-(UMMC), Animal Ethics no:
FAR/10/11/2008/AA(R).
2.5. Total Phenolic Content (TPC). T P Co fC A C Fw a s
determined using Folin-Ciocalteu method [20]. CACF was
prepared in a concentration of 10mg/mL in methanol.
Five microliters of this solution were transferred to 96-well
mircoplate (TPP, USA). To this, 80μL of Folin-Ciocalteu
reagent (1:10) was added and mixed thoroughly. After
5min, 160μL of sodium bicarbonate solution (NaHCO3
7.5%) was added, and the mixture was allowed to stand for
30min with intermittent shaking. Absorbance was measured
at 765nm using microplate reader (Molecular Devices,
Sunnyvale, USA). The TPC was expressed as gallic acid
equivalent (GAE) in mg/g extract and obtained from the
standard curve of gallic acid. The gallic acid standard curve
was established by plotting concentration (mg/mL) versus
absorbance (nm) (y = 0.001x +0 .045; R2 = 0.9975), where
y is absorbance and x is concentration in GAE (n = 3).
2.6. Antioxidant Activity of C. anthelminticum
2.6.1. 1,1-Diphenyl-2-picrylhydrazyl (DPPH) Radical Scav-
enging Activity of CACF. The scavenging activity of CACF
on DPPH was determined using the method described inEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Schematic diagram of extraction/fractionation of C. anthelminticum seeds.
[21]. This method is based on the reduction of purple DPPH
to a yellow-colored diphenyl picrylhydrazine. Changes in
color were measured at 518nm. CACF was tested at ﬁnal
concentrations ranging from 600 to 10μg/mL in ethanol.
One milliliter of 0.3mM DPPH ethanol solution was added
to 2.5mL of sample solution of diﬀerent concentrations to
make the test solutions, while 1mL of ethanol was added
to 2.5mL of samples to make the blank solutions. The
negative control (blank) consisted of 1mL DPPH solution
plus 2.5mL of ethanol. These solutions were allowed to
react at room temperature for 30 minutes in the dark. The
absorbance values were measured at 518nm and converted
into percentage antioxidant activity using the following
equation:
% Inhibition =
(AB −AA)
AB

×100, (1)
where AB is the absorption of blank sample; AA is the
absorption of tested samples.4 Evidence-Based Complementary and Alternative Medicine
The IC50 as well as the kinetics of DPPH scavenging
activitywasdetermined.Ascorbicacidandbutylatedhydrox-
ytoluene (BHT) was used as a positive control in this assay.
2.6.2. ORAC Antioxidant Activity Assay. The oxygen radical
absorbance capacity (ORAC) assay was done based on the
procedure described earlier by Choi et al. [21] with slight
modiﬁcations. Brieﬂy, 175μL of the sample/blank were
dissolved with PBS at concentrations of 160μg/mL, pH
7.4. Serial dilutions of the standard Trolox were prepared
from 75mM. The assay was performed in 96-well black
microplates 25μL of samples (CACF), standard (Trolox),
blank (solvent/PBS), or the positive control (quercetin) was
added to the wells. Subsequently, 150μL of ﬂuorescent
sodium salt solution was added, and the plate was then
incubated for 45 minutes at 37◦C. Twenty ﬁve microliters
of2,20-azobis(2-amidinopropane)dihydrochloride(AAPH)
solution was added for a total volume of 200μL/well.
Fluorescence was recorded until it reached zero (excitation
at 485nm, emission at 535nm) using a ﬂuorescence spec-
trophotometer (Perkin—Elmer LS 55), equipped with an
automatic thermostatic autocell holder at 37◦C. Data were
collected every 2mins for a duration of 2hrs and were
analyzed by calculating the diﬀerences of areas under the
ﬂuorescein decay curve (AUC) between the blank and the
sample. Values were expressed as Trolox equivalents.
2.6.3. Ferric Reducing/Antioxidant Power (FRAP) Assay. The
FRAP assay was slightly modiﬁed from the method of
BenzieandStrain[22].Thestocksolutionsincluded300mM
acetate buﬀer (pH 3.6), 10mM TPTZ (2,4,6-tripyridyl-s-
triazine) solution in 40mM HCl, and 20mM FeCl3·6H2O.
The fresh working solution was prepared by mixing 25mL
acetate buﬀer, 2.5mL TPTZ, and 2.5mL FeCl3·6H2O. The
temperature of the solution was raised to 37◦C before use.
CACF (10μL) was allowed to react with 190μL of the FRAP
solution for 30min in the dark. Colorimetric readings of
the product ferrous tripyridyltriazine complex were taken
at 593nm. The standard curve was linear between 200 and
1000μM FeSO4. Results are expressed as μM Fe (II)/g dry
mass and compared with those of Ascorbic acid and BHT.
2.7. Cell Viability and Cytotoxicity
2.7.1. Cell Culture. All cell lines were obtained from Amer-
ican Type Cell Collection (ATCC) and maintained in a
37◦C incubator with 5% CO2 saturation. Human breast
carcinoma (MCF-7) and normal hepatic (WRL-68) cell lines
were maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM), while nonsmall cell lung cancer cells (A549)
and prostate adenocarcinoma cells (PC-3) were maintained
in RPMI medium. Both media were supplemented with
10% fetus calf serum (FCS), 100 units/mL penicillin, and
0.1mg/mL streptomycin. Cells were cultured using standard
aseptic techniques and were seeded at the indicated densities
below.
2.7.2. Cellular Viability. The inhibitory eﬀects of CACF on
the indicated cell lines’ growth were tested using the MTT
assay [23]. Cells were seeded at a density of 1 × 105cells/mL
in a 96-well plate and incubated for 24 hours at 37◦Ca n d5 %
CO2. Cells were then treated with CACF and incubated for
another 24 hours, after which the MTT solution at 2mg/mL
was added for 1 hour. The insoluble formazan product was
dissolvedinDMSO,andabsorbancewasmeasuredat570nm
using Plate Chameleon V microplate reader (Hidex, Turku,
Finland). Results were expressed as a percentage calculated
from the ratio of absorbance of treated cells to untreated
cells. The concentration that caused a 50% loss of cell growth
(IC50) was used to measure the CACF growth inhibition
potency.
2.8. TNF-α Inhibition Activity of CACF
2.8.1. In Vitro Cell Viability and TNF-α Production Assays.
Murine macrophage cells RAW 264.7 were seeded in 96-well
plates at 5 × 105cells/mL. Cells were either left untreated in
DMEM or pretreated with CACF at the indicated concen-
trations for 30 minutes. Cell stimulation, viability, and TNF
production measurements were conducted exactly as in [24].
Percentage viability was calculated as follows: cell viability
(%) = [(OD570 (sample)/OD570 (control)) ×100].
Whereas percentage TNF inhibition was calculated as
follows:
% inhibition = 100 ×

[TNF] control −[TNF] sample

[TNF] control

,
(2)
where control indicates cells treated in LPS alone.
2.8.2. Measurement of In Vivo Serum TNF. Healthy male rats
were selected and divided into 6 groups (n = 8f o re a c h
group). The rats were pretreated with the indicated solutions
for 30 minutes before lipopolysaccharide (LPS) stimulation:
group 1 was pretreated intraperitoneally (i. p.) with 1mL
of PBS alone, group 2 with dexamethasone (6mg/kg BW)
in 25% DMSO, group 3 with CACF (25mg/kg BW) in 25%
DMSO, group 4 with CACF (50mg/kg BW) in 25% DMSO,
and group 5 with CACF (100mg/kg BW) in 25% DMSO.
Groups 1–5 were treatment groups stimulated with LPS,
while group 6 made up the untreated negative control in
which rats were given a solution of 25% DMSO in PBS
and no LPS. Subsequent to pretreatment, LPS (1mg/kg) was
then administered in 1mL of pyrogen-free normal saline
i. p for ﬁve treatment groups, and PBS was administered
i. p. for the negative control group. Blood was withdrawn
from the animals under ether anesthesia after 90 minutes
of LPS or PBS administration. Serum was collected and
stored at −80◦C until analysis. Serum levels of TNF-α were
determined using rat TNF-α ELISA kit according to the
manufacturer’s protocol (e Bioscience, San Diego, USA).
2.9. Acute Toxicity Study. Healthy adult rats of either sex
were divided into 4 groups (n = 6) and were orally fed
with increasing doses of CACF: 10, 20, 100, and 1000mg/kg
body weight (BW). The rats were observed continuously for
2 hours for behavioral, neurological, and autonomic proﬁlesEvidence-Based Complementary and Alternative Medicine 5
Table 1: Antioxidant activity proﬁle of the chloroform fraction of Centratherum anthelminticum (CACF).
Samples DPPH IC50, μg/mL FRAP (μmol/L) ORAC Equivalent conc. Trolox (20μg/mL (μM)∗∗ IC50 TPC μgG A E / m g
CACF 22.56a ± 1.4 1048.3a ± 21.2 992.34a ± 45.12 86.62 37.16 ±0.85
Ascorbic acid 15a ± 0.3 6240b ± 56.2 — — —
BHT 17a ± 0.4 907.7a ± 54.8 — — —
Quercetin — — 1018.00b ± 34.82 74.52 —
∗The net AUC was calculated by subtracting the blank AUC from the AUC of each sample, the standards, and the positive control. Final ORAC values were
expressed as the equivalent concentration of Trolox (TE) that gives the same level of antioxidant activity as the samples at 20μg/mL. ∗∗Means with diﬀerent
alphabets are statistically signiﬁcant.
and after 24 and 72 hours for any lethality. All procedures
were according to the guidelines stated by OECD.
2.10. NF-κB Translocation Assay. NF-kB translocation in
MCF-7 cells was examined using NF-kB activation HCS
kit which contains Hoechst 33342 and Alexa Fluor 488
conjugated anti-NF-kB dyes. MCF-7 cells were seeded into
96-well plates (Perkin-Elmer Inc., Wellesley, MA, USA) at
6000cells/well. After overnight, cells were treated with diﬀer-
ent concentrations of CACF for 1hr, followed by treatment
with 10μg/mL TNF-α for another 30 minutes. Fixation,
permeabilization, and immunoﬂuorescence staining of cells
were performed according to the manufacturer’s instruc-
tions. ArrayScan reader was used to quantify the diﬀerence
between the intensity of nuclear and cytoplasmic NF-κB-
associated ﬂuorescence, reported as translocation parameter.
2.11. Identiﬁcation and Chemical Analysis Using GC-MS.
Gas chromatography mass spectrometry (GC-MS) analysis
of the selected fraction was carried out on a Shimadzu
GC-17 A network GC system coupled to a mass-selective
detector:MS-QP50-50.SeparationwasconductedonanHP-
5 MS column (30m × 0.32mm × 3.0μm), with helium as
the carrier gas at a ﬂow rate of 1.0mL/min. The injection
volume was 1μL with a split ratio of 10:1. The column
temperature was initially held at 100◦C for 3min and then
increased to 290◦Ca tar a t eo f1 0 ◦C/min. The column
temperature was then maintained at 290◦C for 3min. The
temperatures of the injector and detector were 250◦Ca n d
280◦C, respectively. Mass acquisition was performed in the
range of 40–550 atomic mass units (a. m. u) using electron
impact ionization at 70eV. The major components in this
sample were predicted by a spectral database matching
against the library of National Institute of Standards and
Technology (NIST21 and NIST Wiley).
2.12.StatisticalAnalysis. Experimentalvalueswereexpressed
as the means ± standard deviation (SD) of the number of
experiments indicated in the legends. Statistical signiﬁcance
was assessed using one-way analysis of variance (ANOVA)
followed by a multiple comparison test (Tukey’s post-hoc
test), were P<0.001, P<0.01, and P<0.05 were considered
signiﬁcant. Pearson correlation coeﬃcient was used to assess
the correlation between phenolic content and antioxidant
activities.
3. Results
3.1. Antioxidant Activity. Table 1 provides a summary of the
antioxidant and total phenolic content of CACF. The total
phenolic content of CACF was determined to be 37.16 ±
0.85μgG A E / m ge x t r a c t .
3.1.1. DPPH Scavenging Activity of CACF. CACF exhibited
a signiﬁcant dose-dependent inhibition of DPPH activity
(P<0.05), with an IC50 value of 22.56 ± 1.4μg/mL
(Table 1). Maximal DPPH scavenging activity occurred at
41 ± 1.2μg/mL of CACF with an inhibition of 89%.
3.1.2. Ferric Reducing Antioxidant Power of CACF. CACF
showed a signiﬁcant dose-dependent FRAP value (P<
0.05) with a 1048.3μmol/L for the fraction, while the
positive control used in this study displayed a value of 6240
and 907.7μmol/L for ascorbic acid and BHT, respectively
(Table 1).
3.1.3. ORAC Activity of CACF. The area under the curve
(AUC) was calculated for oxygen radical absorbance capacity
of CACF, trolox, and the positive control quercetin. ORAC
results are demonstrated in Table 1. CACF had an ORAC
value of 992.34 ± 45.12μM trolox equivalent at 20μg/mL.
On the other hand, quercetin had an ORAC value of
1018.00 ±34.82μMo fT r o l o xe q u i v a l e n ta t5μg/mL.
3.2. Cytotoxic Activity of CACF. To evaluate the cytotoxic
activity, CACF was tested with a series of diﬀerent doses
on nonsmall cell lung cancer (A549), prostate cancer (PC-
3), breast cancer (MCF-7), and normal hepatic cells (WRL-
68),respectively.After24hours,cellviabilitywasdetermined
by the MTT assay. CACF induced cell cytotoxicity in
a concentration-dependent manner. These dose titration
curves allowed determination of IC50 for the CACF towards
diﬀerent cell lines. CACF demonstrated dose-dependent
cytotoxic eﬀects with IC50 values of 31.42 ± 5.4, 22.61 ± 1.7,
8.1 ±0.9, and 54.93 ±8.3μg/mL; in A549, PC-3, MCF-7 and
WRL-68,respectively(Figure 2).Inlinewiththesescreening,
reference drug (Paclitaxel) was used as a positive control
whose IC50 on tested A549, PC-3, MCF-7 and WRL-68 were
5.675 ± 1.03, 0.37 ± 0.03, 1.583 ± 0.24, and 0.666 ± 0.05,
respectively. Hence, these results point out that cell lines vary
in their sensitivity.6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: CACF was tested with a series of diﬀerent doses on A549,
MCF-7, PC-3, and WRL-68 cells, respectively. After 24 hours, cell
viability was determined by the MTT assay. Test agents induced
cell cytotoxicity in a concentration-dependent manner. These dose
titrationcurvesalloweddeterminingIC50 forthetestagentstowards
diﬀerent cell lines. The IC50 value of CACF on the viability of A549,
PC-3, MCF-7, and WRL-68 has been determined to be 31.42 ± 5.4,
22.61 ±1.7, 8.1 ±0.9, and 54.93 ±8.3μg/mL, respectively.
3.3. In Vitro Inhibitory Eﬀects of CACF on TNF Production
and RAW264.7 Cell Viability. Stimulation of RAW264.7 with
LPS for 4 hours caused a signiﬁcant increase in TNF-α
production (Figure 3). CACF eﬀectively and dose depen-
dently inhibited TNF-α r e l e a s ew i t ha nI C 50 of 0.012μg/mL
as depicted in Figure 4. CACF exhibited maximal TNF
inhibition of 90% at 0.31μg/mL. This signiﬁcant inhibitory
eﬀectwasobservedatnoncytotoxicdosesrangingfrom0.031
to 0.002μg/mL (Figure 5).
3.4. In Vivo Activity
3.4.1. Acute Toxic Eﬀects of CACF. The acute toxicity study
revealed the nontoxic nature of CACF. There was a 100%
survival rate of the animals treated with CACF at doses
ranging from 10 to 1000mg/kg. Moreover, no toxic eﬀects
were observed throughout the study.
3.4.2. The Inhibitory Eﬀect of CACF on Serum TNF. Stim-
ulation of animals with LPS leads to an increase in serum
TNF levels up to 2ng/mL in rats pretreated with PBS alone.
On the other hand, animals pretreated with dexamethasone
and CACF have shown a signiﬁcant reduction in TNF
levels (Figure 6). Moreover, CACF showed a dose-dependent
inhibitory eﬀect of serum TNF in LPS-stimulated rats, and
this eﬀect in rats pretreated with 100mg/kg was almost 61%,
to that of dexamethasone 67%, respectively.
3.5. CACF Inhibits NF-kB Activity. I nt h i ss t u d y ,w et e s t e d
CACF for its in vitro inhibitory eﬀects against NF-κB
translocation activated by TNF-α and illustrated by HCS
assay. CACF displayed signiﬁcant inhibitory eﬀects on the
activation of NF-κB( Figure 7). In parallel, the morphologi-
cal changes of NF-κB translocation indicated by immunoﬂu-
orescence staining (Figure 8) showed an inhibitory eﬀect of
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Figure 3: The eﬀects of CACF on TNF production in RAW264.7
cells. Cells were pretreated with the indicated concentrations
of CACF, or the TNF inhibitor pentoxifylline (PTX). The cells
were stimulated with LPS (1μg/mL) for four hours or were left
untreated (DMSO). The protein concentration was measured using
ELISA.Dataisrepresentativeofthreeindependentexperimentsand
was analyzed using one-way ANOVA with Tukey’s post hoc test.
The inhibitory eﬀect of CA chloroform fraction was signiﬁcantly
diﬀerent from stimulated cells (LPS) (∗∗∗P<0.001).
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Figure 4: Dose-response eﬀect of the CACF on TNF inhibition:
the chloroform fraction had an IC50 of 0.012μg/mL (LOG IC50:
−1.931).
CACF on TNF-α-induced NF-κB translocation in a dose-
dependent manner. When cells remain untreated, most of
the ﬂuorescence staining for NF-κB were in the cytoplasm
and rare NF-κB staining found in nuclei area. While cells
were stimulated with the TNF-α alone, NF-κB staining
signiﬁcantly increased in nuclei area, suggesting that NF-
κB translocated from cytoplasm into the nucleus. However,
MCF-7 cells were treated with 8, 4, and 2μg/mL of CACF,
and NF-κB translocation induced by TNF-α was inhibited.
3.6. Chemical Composition. The possible chemical composi-
tion of CACF analyzed by GC/MS is presented in (Table 2).
Based on the similarity index out of major peaks, totalEvidence-Based Complementary and Alternative Medicine 7
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Figure 6: Eﬀe c to fC A C Fo ns e r u mT N Fl e v e l si nr a t s .D i ﬀerent
treatment groups were pretreated i.p with 25, 50, and 100mg/kg
of (LPS + CACF), 6mg/kg of dexamethasone (LPS + DEX) or
with phosphate buﬀer saline (LPS + PBS), and DMSO (Untreated)
for 30mins. All the treatment groups were then either injected
with 1mg/kg of lipopolysaccharides (LPS) or with PBS for 90mins.
Blood was withdrawn, and serum TNF was quantiﬁed using ELISA.
One-way ANOVA with Tukey’s post-analysis was used to calculate
thestatisticalsigniﬁcanceamongthegroupswhencomparedtoLPS
+P B S .∗∗∗P<0.001, ∗∗P<0.01, and ∗P<0.05.
22 compounds were detected in this fraction. The most
abundant component comprise of 2-Morpholinoethyl isoth-
iocyanate (29.04%), 1,E-11,Z-13-Octadecatriene (16.48%),
and Octadecanoic acid, butyl ester (16.15%). Eight com-
pounds (<5%) were not reported in Table 2 due to their
minority.
4. Discussion
The current study revealed the pleiotropic bioactivities of
the chloroform fraction of Centratherum anthelminticum
(CACF) seeds. The antioxidant assays performed using the
DPPH, ORAC, and FRAP methodologies revealed the free
radical-scavenging possibilities of this fraction. Antioxidants
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Figure 7: Dose-response histogram of CACF treated MCF-7 cells
for1hoursandthenstimulatedfor30minuteswith10ng/mLTNF-
α for quantitative image analysis of intracellular targets.
are substances that may protect cells from the damage
caused by unstable molecules known as free radicals. Several
factors can lead to the accumulation of free radicals in the
cell; examples are certain chemicals, ultraviolet radiations,
inﬂammatory cytokines, and bacterial lipopolysacharides,
and other pesticides further generate oxidative stress con-
ditions and extend their contribution in the progression
of various ailments including neurodegenerative diseases,
atherosclerosis, diabetes, inﬂammation, and carcinogenesis
[19, 25–27]. However, present work demonstrated that
CACF fraction is grouped with certain antioxidant com-
pounds. Our results warrant the probability of the CACF as
a natural source of antioxidants which could be promising
in hunting free radicals and treating diseases related to free
radical reactions. Hence, the ability to scavenge free radicals
may attenuate the several signalling pathways triggering
tissue damage and inﬂammation, which in turn will have a
protective eﬀect on the cells [28, 29].
Having uncovered the antioxidant nature of CACF, we
then turned to look at its eﬀects in a living cell system.
Cytotoxic screening models provide important preliminary
data to select plant extracts or natural compounds with
potential anticancer properties [30]. In this study, the
cytotoxic eﬀect of CACF was investigated by the addition
of the MTT tetrazolium salt [23] to various cancer cell
lines previously treated with CACF. CACF showed selective
cytotoxic eﬀect on MCF-7 compared with other tested cell
lines with low IC50 value, nevertheless it was not cytotoxic to
normal cell line, WRL-68. These results specify that cell lines
diﬀer in their sensitivity to the same CACF, which may be
determined by multiple-cell type-speciﬁc signalling cascades
and transcription factor activities [31].
In addition to that, CACF exhibited inhibition of TNF
production both in vitro and in vivo without aﬀecting cell
viability and animal survival, respectively. This also warrants
the ethnomedical uses of this plant in the treatment of8 Evidence-Based Complementary and Alternative Medicine
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Figure 8: Stained MCF-7 cells were treated with CACF (8μg/mL) for 1 hour and then stimulated for 30 minutes with 10ng/mL TNF-α
(NF-κB activation).
inﬂammatory conditions. The ability of CACF to inhibit
TNF production may attribute to several factors. Previous
studies on C. anthelminticum have shown the presence of
several bioactive components [18], for example, butein
which is one of the secondary metabolites isolated from the
seeds of this plant shown to possess both antioxidant and
anti-inﬂammatory activities [14]. The ability of CACF to
interferewithinﬂammatorysignallingmayinturnexplainits
cytotoxic eﬀects on cancer cells, since these pathways are also
involved in the survival, proliferation, invasion, angiogenesis
and metastasis of tumours [32].
Moreover, this fraction along with pleotropic bioactivi-
ties demonstrated the in vitro inhibitory eﬀects on cell pro-
liferation in MCF-7 cells, which moves our line of study
towards carrying out additional experiments to get a better
understanding in elucidating mechanisms of breast carcino-
genesis with possible future strategies. It is well known that
antioxidants are known for their ability to scavenge free
radicals from the various stimuli, resulting in activation of
transcription factors involved in the transcription of survival
and inﬂammatory genes such as nuclear factor kappa B
(NF-κB) [24]. NF-κB is a transcription factor involved in
copious inﬂammatory and cancer-related ailments and has
developed as a foremost target in drug discovery [33]. The
consequences of NF-κB transcription factors in constitutive
activation includes increased survival signalling, cell prolif-
eration, angiogenesis, and invasion, which are key features
of the malignant phenotype [34]. Our study demonstrated
that CACF in a concentration-dependent manner inhibited
constitutive activation of NF-kB translocation stimulated by
TNF-α in MCF-7 cells. TNF-α-induced transcript levels for
the adhesion molecules, and this might interfer at an early
stage of signaling event induced by TNF-α. This suggests
that CACF may inhibit the expression of the cell adhesion
molecules by interfering with the transcription of their
respective genes and may inhibit either the initiation of
transcription orthestability of themRNAsencoding in these
molecules. It is well understood that NF-κBi sa ni m p o r t a n t
transcription factor involved in the gene regulation and con-
tributing in immune and inﬂammatory responses, including
genes encoding [35, 36]. Moreover, tumors with constitutive
NF-kB activity have inherent resistance to many anticancer
therapies. Thus, NF-κB is believed to play an important role
in the regulation of inﬂammatory response associated with
cancer therapy [37, 38].
Analysis of the nonpolar extractable of plant material
using GC/MS has been applied before [39]. Our results
demonstrate that CACF contains various bioactive com-
ponents such as 2-morpholinoethyl isothiocyanate which
represents 29.04%. Isothiocyanates have been shown to
inhibit carcinogenesis and also useful as chemopreventive
agentsagainstcancers.Theyworkonavarietyoflevels.These
compounds are shown to induce apoptosis in certain cancer
cell lines and in some cases and are even able to induce
apoptosis in cells that are resistant to some currently used
chemotherapeutic drugs [40–44].Evidence-Based Complementary and Alternative Medicine 9
Table 2: Compounds tentatively identiﬁed in the chloroform fraction of Centratherum anthelminticum (CACF).
Peak number RTa Percentage of
the peakb
Molecular
weight
Molecular
formula
Similarity
index Compoundc
1 5.279 5.97 116 C6H12O2 89 2-Pentanone-4-hydroxy-4-methyl
2 8.086 29.04 172 C7H12N2OS 92 2-Morpholinoethyl isothiocyanate
3 11.278 5.97 180 C6H12O6 85 d-Allose
4 11.547 3.62 346 C22H34O3 65 Drostanolone AC
5 11.650 1.62 162 C10H10O2 62 3(2H)-Benzofuranone,
2,6-dimethyl
6 15.533 6.36 326 C21H42O2 67 Nonadecanoic acid, ethyl ester
7 17.676 16.48 248 C18H32 78 1,E-11,Z-13-Octadecatriene
8 17.933 1.85 312 C20H40O2 68 Hexadecanoic acid,
1,1-dimethylethyl ester
9 17.950 0.45 145 C6H11NO3 46 Adipic acid monoamide
10 17.967 2.45 282 C12H26O5S 55 d-Mannitol, 1-thiohexyl
11 18.117 0.83 173 C7H11NO2 45 Ethyl 4-isothiocyanatobutyrate
12 21.450 16.15 340 C22H44O2 85 Octadecanoic acid, butyl ester
13 23.350 1.68 172 C9H16O3 50
Arabino-hetitol,
2,3:5,6-dianhydro-1,7-dideoxy-
2,6-di-e-methyl
14 23.942 2.62 298 C17H14O5 42
4H-1-Benzopyran-4-one,5-
hydroxy-7-methoxy-2-(3-
methoxyphenyl)
Total 95.09
aRT: retention time (min).
bRelative area percentage (peak area relative to the total peak area percentage).
cCompounds listed in order of their relative area percentage.
In summary, the chloroform fraction of Centratherum
anthelminticum seed (CACF) displayed a range of inter-
related in vitro activities, ranging between antioxidant,
cytotoxic and in vitro and in vivo TNF-α inhibition while
remaining safe. Furthermore, CACF is maintained concern-
ing mechanistic approach linked with cytotoxic activity on
targeted cell line which positively inhibited NF-kB translo-
cation in MCF-7 cells. Therefore, these results merit further
pharmacological investigations with detailed phytochemical
analysis on C. anthelminticum.
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